Natural killer cell therapies in cancer: innovations, challenges, and future directions
NK cell-based therapies represent a promising avenue in cancer immunotherapy but require carefully designed solutions to overcome their inherent limitations. Advances in biomarker-guided patient selection, integration with existing treatment modalities, and international collaboration will be critical for translating NK cell biology into effective and durable clinical outcomes.
Authors
- Yachana Mishra
- Abdelrahim M. Alqudah (ORCID: https://orcid.org/0000-0003-3721-8225)
- Yahia El‐Tanani
- Alaa A. A. Aljabali (ORCID: https://orcid.org/0000-0002-9519-6338)
- Vijay Kumar Mishra (ORCID: https://orcid.org/0000-0001-6542-2464)
- Taher Hatahet (ORCID: https://orcid.org/0000-0003-0171-3304)
- Esam Y. Qnais (ORCID: https://orcid.org/0000-0002-6203-4527)
- Mohamed El‐Tanani (ORCID: https://orcid.org/0000-0002-4735-5445)
- Omar Gammoh (ORCID: https://orcid.org/0000-0001-8801-2652)
Institutions
- University College of the North (CA)
- Lovely Professional University (IN)
- Hashemite University (JO)
- Bangor University (GB)
- Royal Cornwall Hospital Trust (GB)
- Yarmouk University (JO)
- Ras al-Khaimah Medical and Health Sciences University (AE)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14712598.2025.2601053
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00